GLPBio

Immunology/Inflammation

Read More about this category

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

Research Areas

Products Related to Immunology/Inflammation(4543)

  • GC79677 structure
    GC79677STF-1623
    CAS: 2298391-60-1
    Purity: >99.50%

    STF-1623 is a highly potent, selective, cell-impermeable non-covalent ENPP1 inhibitor, with IC 50 values of 0.6 nM and 800 nM against human ENPP1 and ENPP3, respectively.

  • GC79678 structure
    GC79678LIQ1
    CAS: 2606032-80-6
    Purity: >97.00%

    LIQ1, a flavonoid derivative, is a potent Pyruvate kinase M2 ( PKM2 ) allosteric inhibitor ( IC 50 = 0.39 μM; K d = 4.5 μM) targeting Arg43 within the polyarginine pocket.

  • GC79707 structure
    GC79707ST1072
    CAS: 1402703-50-7
    Purity: >98%

    ST1072 is an inhibitor of CerS4 and CerS6.

  • GC79708 structure
    GC79708Alcudacigib TFA
    Purity: >99.00%

    Alcudacigib (ASP1570; DGKζ-IN-1) TFA is an orally active diacylglycerol kinase ζ ( DGKζ ) inhibitor, with an IC 50 of 4.7 nM against human DGKζ and an IC 50 of 3.0 nM against mouse DGKζ. Alcudacigib TFA selectively inhibits the kinase activity of DGKζ and induces proteasome-dependent degradation of DGKζ protein.

  • GC79709 structure
    GC79709HK2-IN-4
    CAS: 2748366-80-3
    Purity: >99.50%

    HK2-IN-4 is a selective hexokinase 2 ( HK2 ) inhibitor with an IC 50 value of 0.79 μM and a K d value of 0.41 μM.

  • GC79724 structure
    GC79724CHI3L1-IN-5
    CAS: 2249043-42-1
    Purity: >98.50%

    CHI3L1-IN-5 (Compound Z17) is a highly selective CHI3L1 inhibitor with a K D value of 6 μM.

  • GC79725 structure
    GC79725DI-1548
    CAS: 2247060-97-3
    Purity: >98%

    DI-1548 is a potent, selective, and irreversible covalent inhibitor of DCN1 ( IC 50 = 4.6 nM).

  • GC79749 structure
    GC79749SHIP1-IN-1
    CAS: 3027375-00-1
    Purity: >99.50%

    SHIP1-IN-1 is an orally active, blood-brain barrier-permeable SHIP1 ligand.

  • GC79757 structure
    GC79757ALOX5 stabilizer-1 TFA
    Purity: >98.00%

    ALOX5 stabilizer-1 TFA is an arachidonate 5-lipoxygenase ( ALOX5 ) stabilizer with a K d of 7.26 μM.

  • GC79758 structure
    GC79758PAI-1-IN-1
    CAS: 1247823-40-0
    Purity: >99.00%

    PAI-1-IN-1 is an orally active and specific PAI-1 inhibitor with an IC 50 of <6.95 μM.

  • GC79803 structure
    GC79803Paeonolsilate sodium
    CAS: 827610-11-7
    Purity: >98%

    Paeonolsilate (sodium) can inhibit ox-LDL-induced macrophage foam cell formation and inflammation in atherosclerosis.

  • GC79804 structure
    GC79804Cupabimod
    CAS: 297774-48-2
    Purity: >91.00%

    Cupabimod is a decoy oligodeoxynucleotide for transcription factor NF-κB.

  • GC79805 structure
    GC798056-Methoxymellein
    CAS: 13410-15-6
    Purity: >99.00%

    6-Methoxymellein, a phytoalexin, is a NF-κB inhibitor.

  • GC79806 structure
    GC79806TKL002
    CAS: 3098518-95-4
    Purity: >98.00%

    TKL002 is a blood-brain barrier-permeable inhibitor of the CTH/H 2 S/NF-κB/EMT signaling axis.

  • GC79807 structure
    GC79807RP-182 acetate
    Purity: >98.50%

    RP-182 acetate is a synthetic immunomodulatory peptide that exerts anti-tumor effects by targeting the mannose receptor CD206 ( K d = 8 μM) on the surface of tumor-associated macrophages (TAMs).

  • GC79808 structure
    GC79808SAR113945 monopotassium
    CAS: 899418-65-6
    Purity: >98%

    SAR113945 monopotassium is a highly selective IKK-β inhibitor with an IC 50 value of 0.4 nM.

  • GC79809 structure
    GC79809TBK1 ligand 3
    CAS: 2115897-10-2
    Purity: >99.00%

    TBK1 ligand 3 is a TBK1 ligand, which can be used as a target protein ligand for the synthesis of PROTAC UNC8209 and UNC8461 [1] .

  • GC79810 structure
    GC79810MLN-0415
    CAS: 1147862-78-9
    Purity: >98.00%

    MLN-0415 is an IKKβ inhibitor.

  • GC79811 structure
    GC79811Tat-IKIP (46-60) TFA
    Purity: >99.50%

    Tat-IKIP (46-60) TFA is the trifluoroacetic acid of Tat-IKIP (46-60).

  • GC79812 structure
    GC79812CDDO-biotin
    CAS: 3110422-01-7
    Purity: >96.50%

    CDDO-biotin is an IKKβ inhibitor with cancer cell inhibitory activity.

  • GC79813 structure
    GC79813Arvelexin
    CAS: 4837-74-5
    Purity: >98.00%

    Arvelexin is a biologically active compound.

  • GC79814 structure
    GC79814Isosorbide di-(methyl fumarate)
    CAS: 2013542-44-2
    Purity: >99.50%

    Isosorbide di-(methyl fumarate) (IDMF), topical DMF derivative, is an NRF2/ARE pathway activator.

  • GC79815 structure
    GC79815(E/Z)-Sinigrin free base
    CAS: 534-69-0
    Purity: >98%

    (E/Z)-Sinigrin ((E/Z)-Allyl-glucosinolate; (E/Z)-2-Propenyl-glucosinolate) free base is an orally active aliphatic thioglucoside anti-leukemia compound.

  • GC79816 structure
    GC79816Cryptolepine
    CAS: 480-26-2
    Purity: >98%

    Cryptolepine is an orally active multi-potent alkaloid with anti-cancer, anti-bacterial, anti-viral, anti-malarial, anti-inflammatory, anti-hyperglycemic, relieve pain and other properties.